covid-19 2020 donates patient

Noveome studies anti-inflammatory drug ST266 in Covid-19

Reading now: 866
www.pharmaceutical-technology.com

Next generation biologics company Noveome Biotherapeutics will evaluate its lead programme ST266 as a potential treatment of severe cytokine storm response associated with Covid-19.

ST266, which was initially developed by Noveome for ophthalmology indications, is a first-of-its-kind cell-free platform biologic drug, composed of hundreds of anti-inflammatory proteins, known as the secretome.

The proteins are collected from donated, full term caesarean-sectioned placentas, which are normally discarded after birth. In clinical trials to date, ST266 has shown to be safe and effective at reducing inflammatory response in humans.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA